Skip Navigation LinksHome > October 2004 - Volume 11 - Issue 5 > Pegvisomant: the role of a growth hormone receptor antagonis...
Current Opinion in Endocrinology & Diabetes:

Pegvisomant: the role of a growth hormone receptor antagonist in the treatment of acromegaly

Ben-Shlomo, Anata; Vivien, Herman-Bonertb; Melmed, Shlomoa

Collapse Box


Purpose of review: Acromegaly treatments do not offer complete remission in 30% of patients. Development of an innovative growth hormone receptor antagonist, pegvisomant, may offer improved disease control as it directly reduces peripheral insulinlike growth factor I synthesis.

Recent findings: Pegvisomant is a mutated growth hormone analogue that prevents functional dimerization of the growth hormone receptor therefore fails to elicit growth hormone -signal transduction pathways and insulinlike growth factor I synthesis and secretion. More than 90% of patients exhibit normal insulinlike growth factor I levels with pegvisomant treatment. Soft-tissue swelling, excessive perspiration, fatigue, and glucose tolerance are markedly improved. Pituitary tumors have enlarged in a few treated patients; some had liver function abnormalities, and all exhibited increased growth hormone levels. Other minor side effects included reversible injection site reactions, musculoskeletal pain, diarrhea, and nausea. Concerns regarding long-term effects include pituitary tumor size progression or development of somatotroph cell hyperplasia, which may be related to the observed increase of circulating growth hormone levels; liver function abnormalities; formation of anti–growth hormone antibodies; and development of growth hormone deficiency. Insulinlike growth factor I measurements are the only reliable monitoring system because growth hormone levels are elevated during drug treatment.

Summary: Pegvisomant is most efficacious in reducing insulinlike growth factor I levels in patients with acromegaly, and a careful controlled assessment of long-term effects is required to evaluate its place in the long-term treatment of acromegaly.

© 2004 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.